No data exist for prescribing hydroxychloroquine for post-exposure prophylaxis, and we should not prescribe it for this indication.... [Read More]
Rheumatology in the Age of COVID-19: HCQ Shortages Driven by Small, Nonrandomized Study
Search results for: "Michael Putman"
New ACR/ARP Committee Members Are Ready to Work
Editor’s note: Volunteer nominations for the ACR and Foundation Board of Directors and all standing committees are open until June 1. Volunteering is a great way to give back and can be truly meaningful. Myriad worthwhile causes exist, so it can be hard to choose among them, but donating time to ACR and ARP committees… [Read More]
FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations
The U.S. Food & Drug Administration (FDA) approved nintedanib for systemic sclerosis associated interstitial lung disease (SSc-ILD) on Sept. 6 after a randomized, controlled trial (SENSCIS) demonstrated significant benefit against placebo.1 At a cost of $96,000 per year, treatment reduced the adjusted annual rate of change in forced vital capacity (FVC) from –93.3 mL in… [Read More]
For Residents, Mystery Patients Often Require Rheumatologist Advice
As a first-year internal medicine resident, I find myself consulting rheumatologists for just about every mystery patient in our hospital. Like many residents, I was initially intimidated by the complexity of this elusive field. At first glance, diagnosis and management seem completely inaccessible to a first-year resident. But several rheumatology consults later, I can confidently… [Read More]